Biotech Values

[DewDiligence]

Update on DYAX’s program in Cystic Fibrosis:

Today’s guidance is essentially unchanged from DYAX’s 12/15/03 PR announcing U.S. orphan-drug status for DX-890 in CF. It looks like DYAX has a good chance to be the first to market in this orphan indication, which would confer seven years of marketing exclusivity. DX-890 also has CF orphan status in Europe. Despite a big rise in the past year, DYAX remains a pretty cheap stock; I don’t have any position at this time.

http://biz.yahoo.com/bw/040218/185224_1.html

>>
In collaboration with Debiopharm S.A., we will be announcing results from the Phase IIa study of DX-890 in children with CF in the very near term. Debiopharm is also planning to initiate a larger Phase II trial of DX-890 in CF in the second half of 2004.
<<